Andrea L. Wellington

Array ( [id] => 17133709 [patent_doc_number] => 11135245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Engineered gd T-cells [patent_app_type] => utility [patent_app_number] => 14/944106 [patent_app_country] => US [patent_app_date] => 2015-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 30415 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14944106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10774751 [patent_doc_number] => 20160120907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 14/934256 [patent_app_country] => US [patent_app_date] => 2015-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 14749 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14934256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18853908 [patent_doc_number] => 11851469 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-26 [patent_title] => Soluble heterodimeric T cell receptor, and preparation method and use thereof [patent_app_type] => utility [patent_app_number] => 15/524370 [patent_app_country] => US [patent_app_date] => 2015-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 100 [patent_no_of_words] => 15208 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15524370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942128 [patent_doc_number] => 20170246279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'COMPOSITIONS AND METHODS FOR BOOSTING THE EFFICACY OF ADOPTIVE CELLULAR IMMUNOTHERAPY' [patent_app_type] => utility [patent_app_number] => 15/521794 [patent_app_country] => US [patent_app_date] => 2015-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17274 [patent_no_of_claims] => 75 [patent_no_of_ind_claims] => 47 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15521794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11040194 [patent_doc_number] => 20160237150 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-18 [patent_title] => 'MODULATED LYSINE VARIANT SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/923966 [patent_app_country] => US [patent_app_date] => 2015-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 56868 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14923966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700560 [patent_doc_number] => 20160046708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION' [patent_app_type] => utility [patent_app_number] => 14/923958 [patent_app_country] => US [patent_app_date] => 2015-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 28715 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14923958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11612597 [patent_doc_number] => 09650445 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Immunotherapeutic molecules and uses' [patent_app_type] => utility [patent_app_number] => 14/918807 [patent_app_country] => US [patent_app_date] => 2015-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 10 [patent_no_of_words] => 34971 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14918807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14174177 [patent_doc_number] => 10261093 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Isolating cells expressing secreted proteins [patent_app_type] => utility [patent_app_number] => 14/885460 [patent_app_country] => US [patent_app_date] => 2015-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 59 [patent_no_of_words] => 15820 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14885460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685858 [patent_doc_number] => 20160032003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'Therapeutic Use of Anti-CD22 Antibodies for Inducing Trogocytosis' [patent_app_type] => utility [patent_app_number] => 14/884313 [patent_app_country] => US [patent_app_date] => 2015-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 34674 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14884313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992429 [patent_doc_number] => 20170296584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'METHODS FOR EXPANDING T CELL POPULATIONS' [patent_app_type] => utility [patent_app_number] => 15/517339 [patent_app_country] => US [patent_app_date] => 2015-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8757 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15517339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10700762 [patent_doc_number] => 20160046909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells' [patent_app_type] => utility [patent_app_number] => 14/863274 [patent_app_country] => US [patent_app_date] => 2015-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9608 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14863274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476151 [patent_doc_number] => 20150361168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'PURIFIED ANTIBODY COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/841439 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 64085 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476152 [patent_doc_number] => 20150361169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'PURIFIED ANTIBODY COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/841474 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 64088 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13093367 [patent_doc_number] => 10066015 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-09-04 [patent_title] => CD3 binding domains [patent_app_type] => utility [patent_app_number] => 14/820462 [patent_app_country] => US [patent_app_date] => 2015-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 6927 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14820462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729644 [patent_doc_number] => 20160075793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/815562 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30869 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729859 [patent_doc_number] => 20160076009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/815583 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30869 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729645 [patent_doc_number] => 20160075794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/815604 [patent_app_country] => US [patent_app_date] => 2015-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30865 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14815604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980012 [patent_doc_number] => 20160176957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Use of TNFalpha Inhibitor' [patent_app_type] => utility [patent_app_number] => 14/809828 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23896 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14809828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980012 [patent_doc_number] => 20160176957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Use of TNFalpha Inhibitor' [patent_app_type] => utility [patent_app_number] => 14/809828 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23896 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14809828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10699433 [patent_doc_number] => 20160045580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-18 [patent_title] => 'IDENTIFICATION OF CD8+ T CELLS THAT ARE CD161HI AND/OR IL18R(ALPHA)HI AND HAVE RAPID DRUG EFFLUX CAPACITY' [patent_app_type] => utility [patent_app_number] => 14/810286 [patent_app_country] => US [patent_app_date] => 2015-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 13268 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14810286 [rel_patent_id] =>[rel_patent_doc_number] =>)